GU Oncology Now Editors

GU Oncology Now

After the VISION trial showed that therapy with the radioligand, 177Lu-PSMA, was effective in patients with advanced metastatic castration-resistant prostate cancer (mCRPC), researchers, led by Masatoshi Hotta, MD, assessed 177Lu-PSMA treatment outcomes in patients who would have been a screen failure (SF) under the VISION trial&rsquo;s PSMA-PET/CT inclusion criteria. The findings were presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.According to Dr. Hotta, SF patients attained worse outcomes compared to VISION-eligible patients. This finding opposed the position of some investigators who, noting the low SF rate in the VISION study, suggested that eligibility screening prior to 177Lu-PSMA treatment is unnecessary.The final analysis included 301 patients who had been treated with one or more cycles of 177Lu-PSMA. The two criteria for SF from the VITAL trial were: an absence of metastatic lesions plus low/no PSMA expression, and a presence of one or more metastatic lesions measurable by CT. The cohort was largely composed of eligible patients (272/301), and a smaller group of SF patients (29/301). Compared to VISION-eligible patients, SF patients had a worse prostate-specific antigen &gt;50% response rate (PSA50RR) (p = 0.005), overall PSARR (p = 0.003), median PSA progression-free survival (p = 0.023), and a typically lower median overall survival (p = 0.16).Dr. Hotta and colleagues supported the continued use of PSMA-PET eligibility screening for 177Lu-PSMA therapy, though they noted that &ldquo;refinements in patient selection for 177Lu-PSMA are needed to optimize patient outcomes.&rdquo;Ultimately, while the authors acknowledged that optimal treatment plans for negative or low PSMA-expressing lesions were underexplored, they suggested that &ldquo;combining 177Lu-PSMA therapy with external-beam [radiation therapy (RT)] and/or with other systemic therapy may be an effective therapeutic approach.&rdquo;

Outcomes of 177Lu-PSMA Therapy in Patients who Failed Screening for the VISION Trial

American Society of Clinical Oncology Genitourinary Cancers Symposium 2022

ASCO GU Symposium 2022

177Lu-PSMA Therapy in Patients Who Failed VISION Screening

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe